Display options
Cite
Nygaard HB, Wagner AF, Bowen GS, et al. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res Ther. 2015;7(1):35doi: 10.1186/s13195-015-0119-0.
Nygaard, H. B., Wagner, A. F., Bowen, G. S., Good, S. P., MacAvoy, M. G., Strittmatter, K. A., Kaufman, A. C., Rosenberg, B. J., Sekine-Konno, T., Varma, P., Chen, K., Koleske, A. J., Reiman, E. M., Strittmatter, S. M., & van Dyck, C. H. (2015). A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimer's research & therapy, 7(1), 35. https://doi.org/10.1186/s13195-015-0119-0
Nygaard, Haakon B, et al. "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease." Alzheimer's research & therapy vol. 7,1 (2015): 35. doi: https://doi.org/10.1186/s13195-015-0119-0
Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K, Koleske AJ, Reiman EM, Strittmatter SM, van Dyck CH. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease. Alzheimers Res Ther. 2015 Apr 14;7(1):35. doi: 10.1186/s13195-015-0119-0. eCollection 2015. PMID: 25874001; PMCID: PMC4396171.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Res Ther. 2015 Apr 14;7(1):35. doi: 10.1186/s13195-015-0119-0. eCollection 2015.

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.

Alzheimer's research & therapy

Haakon B Nygaard, Allison F Wagner, Garrett S Bowen, Susan P Good, Martha G MacAvoy, Kurt A Strittmatter, Adam C Kaufman, Brian J Rosenberg, Tomoko Sekine-Konno, Pradeep Varma, Kewei Chen, Anthony J Koleske, Eric M Reiman, Stephen M Strittmatter, Christopher H van Dyck

Affiliations

  1. Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut USA ; Department of Neurology, Yale University School of Medicine, New Haven, Connecticut USA ; Program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR), Yale University School of Medicine, New Haven, Connecticut USA ; Current address: University of British Columbia, Division of Neurology, Djavad Mowafaghian Centre for Brain Health, Vancouver, Canada.
  2. Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut USA ; Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut USA.
  3. Program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR), Yale University School of Medicine, New Haven, Connecticut USA.
  4. Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, Connecticut USA.
  5. Department of Neurology, Yale University School of Medicine, New Haven, Connecticut USA.
  6. Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut USA.
  7. Banner Alzheimer's Institute, Phoenix, Arizona USA.
  8. Program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR), Yale University School of Medicine, New Haven, Connecticut USA ; Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, Connecticut USA.
  9. Department of Neurology, Yale University School of Medicine, New Haven, Connecticut USA ; Program in Cellular Neuroscience, Neurodegeneration and Repair (CNNR), Yale University School of Medicine, New Haven, Connecticut USA.
  10. Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut USA ; Department of Neurology, Yale University School of Medicine, New Haven, Connecticut USA ; Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut USA.

PMID: 25874001 PMCID: PMC4396171 DOI: 10.1186/s13195-015-0119-0

Abstract

INTRODUCTION: Despite significant progress, a disease-modifying therapy for Alzheimer's disease (AD) has not yet been developed. Recent findings implicate soluble oligomeric amyloid beta as the most relevant protein conformation in AD pathogenesis. We recently described a signaling cascade whereby oligomeric amyloid beta binds to cellular prion protein on the neuronal cell surface, activating intracellular Fyn kinase to mediate synaptotoxicity. Fyn kinase has been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new therapeutic target for AD. Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.

METHODS: The study was a 4-week Phase Ib multiple ascending dose, randomized, double-blind, placebo-controlled trial of AZD0530 in AD patients with Mini-Mental State Examination (MMSE) scores ranging from 16 to 26. A total of 24 subjects were recruited in three sequential groups, with each randomized to receive oral AZD0530 at doses of 50 mg, 100 mg, 125 mg, or placebo daily for 4 weeks. The drug:placebo ratio was 3:1. Primary endpoints were safety, tolerability, and cerebrospinal fluid (CSF) penetration of AZD0530. Secondary endpoints included changes in clinical efficacy measures (Alzheimer's Disease Assessment Scale - cognitive subscale, MMSE, Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Clinical Dementia Rating Scale - Sum of Boxes) and regional cerebral glucose metabolism measured by fluorodeoxyglucose positron emission tomography.

RESULTS: AZD0530 was generally safe and well tolerated across doses. One subject receiving 125 mg of AZD0530 was discontinued from the study due to the development of congestive heart failure and atypical pneumonia, which were considered possibly related to the study drug. Plasma/CSF ratio of AZD0530 was 0.4. The 100 mg and 125 mg doses achieved CSF drug levels corresponding to brain levels that rescued memory deficits in transgenic mouse models. One-month treatment with AZD0530 had no significant effect on clinical efficacy measures or regional cerebral glucose metabolism.

CONCLUSIONS: AZD0530 is reasonably safe and well tolerated in patients with mild-to-moderate AD, achieving substantial central nervous system penetration with oral dosing at 100-125 mg. Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT01864655. Registered 12 June 2014.

References

  1. EMBO J. 2011 May 18;30(10):2057-70 - PubMed
  2. J Biol Chem. 2011 Nov 4;286(44):37955-63 - PubMed
  3. BMC Neurosci. 2010 Oct 14;11:130 - PubMed
  4. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9 - PubMed
  5. Hum Mol Genet. 2012 Mar 1;21(5):1138-44 - PubMed
  6. Alzheimers Res Ther. 2014 Feb 05;6(1):8 - PubMed
  7. J Neurosci. 2010 May 5;30(18):6367-74 - PubMed
  8. Neurology. 1997 May;48(5 Suppl 6):S10-6 - PubMed
  9. Clin Ther. 2013 Oct;35(10):1480-9 - PubMed
  10. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2295-300 - PubMed
  11. J Biol Chem. 2005 Oct 21;280(42):35119-25 - PubMed
  12. J Neurosci. 2004 Mar 3;24(9):2304-12 - PubMed
  13. Cancer Sci. 2010 Oct;101(10):2186-92 - PubMed
  14. Ann Neurol. 1980 May;7(5):486-8 - PubMed
  15. Neuroimage. 2010 Jun;51(2):654-64 - PubMed
  16. Nat Commun. 2011 Jun 07;2:336 - PubMed
  17. Neurology. 1993 Nov;43(11):2412-4 - PubMed
  18. J Med Chem. 2006 Nov 2;49(22):6465-88 - PubMed
  19. Clin Cancer Res. 2010 Oct 1;16(19):4876-83 - PubMed
  20. Nature. 2009 Feb 26;457(7233):1128-32 - PubMed
  21. Neuron. 2013 Sep 4;79(5):887-902 - PubMed
  22. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  23. J Neurosci. 2009 Aug 26;29(34):10582-7 - PubMed
  24. Alzheimers Res Ther. 2011 Apr 19;3(2):16 - PubMed
  25. J Neurosci. 2007 Jan 24;27(4):796-807 - PubMed
  26. J Psychiatr Res. 1975 Nov;12(3):189-98 - PubMed
  27. J Biol Chem. 2011 Apr 29;286(17):15095-105 - PubMed
  28. J Cell Sci. 1998 Nov;111 ( Pt 21):3167-77 - PubMed
  29. EMBO Mol Med. 2010 Aug;2(8):306-14 - PubMed
  30. J Bone Miner Res. 2010 Mar;25(3):463-71 - PubMed
  31. J Neurosci. 2008 Dec 31;28(53):14537-45 - PubMed
  32. Nat Neurosci. 2012 Sep;15(9):1227-35 - PubMed
  33. Bone. 2012 Apr;50(4):885-92 - PubMed
  34. Mol Oncol. 2009 Jun;3(3):248-61 - PubMed
  35. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1737-42 - PubMed
  36. J Neurosci. 2012 Nov 21;32(47):16857-71a - PubMed
  37. J Biol Chem. 2010 Aug 20;285(34):26377-83 - PubMed
  38. Nature. 2002 Apr 4;416(6880):535-9 - PubMed
  39. Ann Neurol. 2015 Jun;77(6):953-71 - PubMed
  40. J Neurosci. 2011 Nov 9;31(45):16292-7 - PubMed
  41. Neuropathol Appl Neurobiol. 2010 Oct;36(6):462-77 - PubMed
  42. Leuk Res. 2011 Sep;35(9):1273-5 - PubMed
  43. Am J Psychiatry. 1984 Nov;141(11):1356-64 - PubMed
  44. J Neurosci. 2011 May 18;31(20):7259-63 - PubMed

Publication Types

Grant support